- Profile
- prev
- next
General
-
Headquarters
Syracuse, New York, United States
-
Founders & Team
Kelsey Moody
-
Year Founded
2018
-
Company type
Private company
-
Funding stage
Seed
-
Total funding ($M)
10
Technical Details
-
Aging Target
Cellular senescence
-
Disease indication
Osteoarthritis, frailty
-
Product modality
small molecule drugs
-
Clinical stage
Pre-clinical
About
FoxBio, Inc. is a joint partnership between Juvenescence and Antoxerene, a subsidiary of growing discovery/preclinical CRO Ichor Therapeutics. The company is focused on developing small molecule senolytics targeting a major survival pathway relied on by senescent cells.
Cellular senescence is an irreversible arrest in cell proliferation that occurs in response to severe stresses, including telomere shortening, oncogene activation, DNA damage, and oxidative stress. Senescent cells remain metabolically active and secrete inflammatory molecules, termed the senescence-associated secretory phenotype (SASP), which are linked to many diseases of aging.
Ichor Therapeutics, Inc. is a premier, vertically integrated contract research organization that provides pre-clinical research services for aging pathways. Antoxerene works to identify and develop novel compounds to attack disease related to aging. Juvenescence will support the venture with equity financing and drug development expertise